TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
|
LATEST DATA IN THE GLIOBLASTOMA STUDY SNO Poster Nov 2022: Positive updated results from NOX-A12 Phase 1/2 GLORIA trial in GBM presented at the 2022 SNO Annual Meeting |
Press ReleaseBerlin, Germany 2023, January 30 06:00 p.m. TME Pharma announces results of the extraordinary general meeting of shareholders 2023, January 23 08:00 a.m. TME Pharma provides clinical update on the GLORIA expansion arm testing NOX-A12 in combination with radiotherapy and bevacizumab in patients with glioblastoma 2023, January 20 06:00 p.m. Half-yearly report on the liquidity contract with Invest Securities |
Events24th Invest Securities Bio-Med Forum
Aram Mangasarian |